NCT00770497CompletedPhase 2
Effect of Pioglitazone Compared to a Combination Therapy With Ramipril and to a Ramipril Monotherapy on Low Grade Inflammation and Vascular Function in Patients With Increased Cardiovascular Risk and an Activated Inflammation. A Randomized Double-blinded Phase II Study.
Takeda0 sites172 target enrollmentStarted: March 2007Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 172
- Primary Endpoint
- Change in the high-sensitivity C-reactive Protein value.
Study Overview
Brief Summary
The purpose of this study is to determine the effects of pioglitazone, once daily (QD), on low grade inflammation and vascular function in hypertensive patients.
Detailed Description
Patients with insulin resistance and an activated inflammation are prone for cardiovascular complications like myocardial infarction or stroke. Pharmacological interventions reducing vascular inflammation are thought to reduce cardiovascular risk in diabetic and in non-diabetic patients.
Intervention with ACE inhibitors like ramipril is an established and widely used treatment for patients with high blood pressure, proven to reduce cardiovascular risk. Treatment of non-diabetic patients with pioglitazone has shown to improve the cardiovascular risk profile in non-diabetic patients beyond its effect on blood glucose levels.
The purpose of this study is to evaluate effects on low grade inflammation and vascular function of pioglitazone in non-diabetic, hypertensive patients with pre treatment with angiotensin converting enzyme inhibitors (that will be replaced by the study medication at time of randomization).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 30 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Has arterial hypertension.
- •Is on stable treatment with an Angiotensin Converting Enzyme inhibitor at least for 12 weeks.
- •Has a high sensitive C-Reactive Protein value greater than 1.0 mg/L and less than 10.0 mg/L.
- •Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.
Exclusion Criteria
- •Manifests or has newly detected diabetes mellitus type 2 according to World Health Organization criteria.
- •Has Type 1 Diabetes.
- •Has acute infections.
- •Chronic inflammatory diseases which cause elevated CRP-values (e.g. rheumatic diseases, pyelonephritis or osteomyelitis).
- •Use of acetyl salicylic acid and/or Non-steroidal Anti-inflammatory Drugs or Cox-2-inhibitors within the last 4 weeks prior to screening visit, use of Rifampicin within the last 12 weeks prior to screening visit.
- •Uncontrolled hypertension (repeated blood pressure greater than 180/100 mmHg for at least three times within two weeks); persistent hypotension (systolic less than 90 mmHg) or hemodynamic instability.
- •Anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structures.
- •History of severe or multiple allergies.
- •Treatment with any other investigational drug within 3 months before trial entry.
- •Has a progressive, fatal disease.
- •History of drug or alcohol abuse within the last 5 years.
- •A history of significant cardiovascular (New York Heart Association stage I - IV, hemodynamic relevant aortic or mitral valve stenosis, hypertrophic obstructive cardiomyopathy), respiratory, gastrointestinal, hepatic (alanine aminotransferase greater than 2.5 times the normal reference range), renal (creatinine greater than 2.0 mg/dL), or hematological disease, history of macular edema.
- •State after kidney transplantation, hemodynamic relevant renal artery stenosis (bilateral or unilateral in case of single kidney).
- •Blood donation within the last 30 days.
- •Serum potassium greater than 5.5 mmol/L.
- •History of hyperaldosteronism.
- •Treatment with thiazolidinediones within 3 months prior to screening.
- •Acute myocardial infarction, open heart surgery or cerebral events (stroke/transient ischemic attack) within 30 days prior to screening visit.
- •If statin therapy applicable: Change of medication within the last 12 weeks.
- •History of angioneurotic edema (hereditary or idiopathic as consequence of previous Angiotensin Converting Enzyme inhibitor treatment).
- •Dialysis or hemofiltration.
- •Low Density Lipoprotein apheresis with dextran sulphate.
- •Allergic to toxic agents derived from insects.
Arms & Interventions
Pioglitazone 15 mg to 30 mg QD
Experimental
Intervention: Pioglitazone (Drug)
Pioglitazone 15 mg to 30 mg QD + Ramipril 2.5 mg to 5 mg QD
Active Comparator
Intervention: Pioglitazone and ramipril (Drug)
Ramipril 2.5 mg to 5 mg QD
Active Comparator
Intervention: Ramipril (Drug)
Outcomes
Primary Outcomes
Change in the high-sensitivity C-reactive Protein value.
Time Frame: Week: 12.
Secondary Outcomes
- Change from Baseline in Glucose tolerance as assessed by an oral glucose tolerance test.(Week: 12.)
- Change from Baseline in Insulin sensitivity according to the Homeostatic Model Assessment - Sensitivity score and Insulin Secretion.(Weeks: 6 and 12.)
- Change from Baseline in Glycosylated Hemoglobin levels.(Week: 12.)
- Change from Baseline in C-Peptide levels.(Weeks: 6 and 12.)
- Change from Baseline in Proinsulin intact levels.(Weeks: 6 and 12.)
- Change from Baseline in 24 hours Blood Pressure Profile.(Week: 12.)
- Change from Baseline in high-sensitivity C-reactive Protein levels.(Weeks: 6 and 10.)
- Change from Baseline in Adiponectin levels.(Weeks: 6 and 12.)
- Change from Baseline in Monocyte Chemoattractant Protein-1 levels.(Weeks: 6 and 12.)
- Change from Baseline in Matrix metalloproteinase-9 levels.(Weeks: 6 and 12.)
- Change from Baseline in P-selectin levels.(Weeks: 6 and 12.)
- Change from Baseline in Plasminogen Activator Inhibitor-1 levels.(Weeks: 6 and 12.)
- Change from Baseline in Relaxin levels.(Weeks: 6 and 12.)
- Change from Baseline in Endothelin 1-21 levels.(Weeks: 6 and 12.)
- Change from Baseline in Nitrotyrosine levels.(Weeks: 6 and 12.)
- Change from Baseline in Asymmetric Dimethylarginine levels.(Weeks: 6 and 12.)
- Change from Baseline in Myeloperoxidase levels.(Weeks: 6 and 12.)
- Change from Baseline in levels of Oxidative Stress as assessed by Per-Ox-Assay.(Weeks: 6 and 12.)
- Change from Baseline in Total Cholesterol levels.(Weeks: 6 and 12.)
- Change from Baseline in Triglycerides levels.(Weeks: 6 and 12.)
- Change from Baseline in High Density Lipoprotein levels.(Weeks: 6 and 12.)
- Change from Baseline in Low Density Lipoprotein levels.(Weeks: 6 and 12.)
- Change from Baseline in Oxidized Low Density Lipoprotein levels.(Weeks: 6 and 12.)
- Change from Baseline in Soluble Intercellular Adhesion Molecule levels.(Weeks: 6 and 12.)
- Change from Baseline in Soluble Vascular Cell Adhesion Molecule levels.(Weeks: 6 and 12.)
- Change from Baseline in Osteoprotegrin levels.(Weeks: 6 and 12.)
- Change from Baseline in 11-dihydroxy-thromboxan B2 levels.(Weeks: 6 and 12.)
- Change from Baseline in Placental Growth Factor levels.(Weeks: 6 and 12.)
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Effect of Pioglitazone compared to a combination therapy with Ramipril and to a Ramipril monotherapy on low grade inflammation and vascular function in patients with increased cardiovascular risk and an activated inflammationA randomized double-blinded phase II studyon-diabetic hypertensive patients with a hsCRP value > 1.0 mg/L < 10.0 mg/L and pretreated with ACE inhibitors for at least 12 weeks are eligible for study participation.MedDRA version: 8.1Level: LLTClassification code 10003601Term: AtherosclerosisEUCTR2006-004028-35-DETakeda Pharma GmbH
Completed
Phase 3
Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes MellitusDiabetes MellitusNCT00225277Takeda547
Completed
Not Applicable
Effects of the addition of low-dose pioglitazone to combined flutamide-metformin treatment on endocrine-metabolic and body composition indices in young women with ovarian hyperandrogenism, hyperinsulinism and cardiovascular riskISRCTN12871246Hospital Sant Joan de Deu, University of Barcelona (Spain)38
Completed
Phase 3
Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.Diabetes MellitusNCT00225264Takeda458
Completed
Phase 2
Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes MellitusDiabetes MellitusNCT00762736Takeda704